Finance

Lists
Why is KYTX up 3,40%?
Dive Deeper
KYTX:NASDAQ
Kyverna Therapeutics Inc
6,39 $
+3,40%
(+0,21) 1D
6,39 $
0,00% (0,00)
After hours
Closed: 9 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KYTX...
Open
6,20 $
High
6,58 $
Low
6,18 $
Mkt. cap
395,18 млн
Avg. vol.
906,89 м.
Volume
876,45 м.
52-wk high
13,67 $
52-wk low
5,96 $
EPS
-2,94 $
Shares outstanding
61,84 млн
No. of employees
149
Open
6,20 $
High
6,58 $
Low
6,18 $
Mkt. cap
395,18 млн
Avg. vol.
906,89 м.
Volume
876,45 м.
52-wk high
13,67 $
52-wk low
5,96 $
EPS
-2,94 $
Shares outstanding
61,84 млн
No. of employees
149
News stories
From web sources and news partners
About Kyverna Therapeutics Inc
CEO-
Employees149
Founded2018
HeadquartersEmeryville, Калифорния, Америка Құрама Штаттары
Sector-
Websitekyvernatx.com
Analyst ratings
Based on 4 analysts giving stock ratings to KYTX in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for KYTX in the last 3 months.
Highest
Current 6,39 $
33,00 $ (+416,43%)
Average
30,33 $ (+374,65%)
Lowest
25,00 $ (+291,24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
25,00 $
+291,2%
09/25/2026
Derek Archila
Wells Fargo
Buy
Reiterated
33,00 $
+416,4%
09/25/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
09/24/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
33,00 $
+416,4%
08/12/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/12/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
29,00 $
+353,8%
05/13/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
30,00 $
+369,5%
03/30/2026
Last report
2026 ж. 11 там.
Fiscal period
Q2 2026
-0,63 $ / -0,68 $
+7,28%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
-
-
-
-
Cost of goods sold
30,46 млн
-103,71 млн
30,07 млн
-
Cost of revenue
30,46 млн
-103,71 млн
30,07 млн
-
Research and development expenses
-
133,72 млн
-
24,79 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,27 млн
9,27 млн
11,29 млн
14,77 млн
Operating expense
8,27 млн
142,99 млн
11,29 млн
39,56 млн
Total operating expenses
38,73 млн
39,28 млн
41,37 млн
39,56 млн
Operating income
-38,73 млн
-39,28 млн
-41,37 млн
-39,56 млн
Other non operating income
-53,00 мың
17,00 мың
-21,00 мың
-18,00 мың
EBT including unusual items
-36,79 млн
-37,80 млн
-39,73 млн
-38,32 млн
EBT excluding unusual items
-36,79 млн
-37,80 млн
-39,73 млн
-38,32 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-36,79 млн
-37,80 млн
-39,73 млн
-38,32 млн
Net profit margin
-
-
-
-
Earnings per share
-0,85
-0,80
-0,66
-0,63
Interest and investment income
2,00 млн
1,90 млн
2,33 млн
1,93 млн
Interest expense
-7,00 мың
-444,00 м.
-667,00 м.
-674,00 м.
Net interest expenses
1,99 млн
1,46 млн
1,66 млн
1,26 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-37,84 млн
-38,91 млн
-41,02 млн
-39,12 млн
Gain or loss from assets sale
40,00 мың
20,00 мың
-
-47,00 мың
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары